About Us Locations Disclaimer

Dr. R. deGoma

Home
Prevention 2011
Who Needs Prevention
Benefits of Prevention
Risk Assessment
Advanced Lipid Therapy
Stent vs Medical Therapy
Specialized Center
Performance Data
Employer Mandate
Employee Prevention
Patient Mentoring
Coronary Calcium Score
Women & Heart Disease
NJPreventiveCardiology.com

 

Click here for NJ Preventive Cardiology practice brochure

 

Mentoring Program

The Million Hearts Initiative

For Physicians:

Practical Tips for Clinicians

For Communities:

Heart2Heart Talk

For Employers and Employees: You and Health Reform

     



 

Not all cholesterol tests are created equal.

Which leads to more plaque formation - higher LDL cholesterol content or higher LDL particle number?

 

  The traditional testing for cholesterol measures the amount of cholesterol within the LDL particles. LDL is a carrier for cholesterol. Apo B100 is a main protein component of LDL. Atherosclerotic plaque is the result of chronic inflammatory response to oxidized LDL particles within the arterial wall, not due to the cholesterol content itself.

 

  In the above example, the LDL cholesterol is 85 in both A and B. In A, the LDL particle is larger and is able to carry more cholesterol than B. Two LDL particles in A carry as much cholesterol as three LDL particles in B. Patient B has more LDL particles than Patient A while LDL cholesterol level is the same. LDL-P in Patient A is 900. LDL-P in Patient B is 1250. The treatment goal is LDL-P less than 1000.

 

  Knowing the LDL cholesterol level is not enough. The greater the number of LDL particles floating in the blood, the greater the risk. Treatment is aimed to reduce the number of LDL particles to below a target level depending upon the level of risk.

Emil M. deGoma, MD, FACC

Medical Director,

UPenn Preventive Cardiovascular  Program

Health Premium Discount

Lower your risk for heart attack and stroke using evidence-based therapies and become eligible for a substantial premium discount by 2014.
Health Reform 2010
Prevention and Wellness Summary Provisions
Relay Health
Contact Office for Non-Urgent Matters

 

We Support Million Hearts Initiative

 

497,470 Preventable CHD Deaths Annually with Evidence-based Medical Therapy

 

JAMA: 38% of Nonacute Stents Called into Question

 

Optimal Medical Therapy Still Underused in CHD

 

Legacy Effects of Statin Therapy - Reduction in All-Cause Mortality

 

SG2 Expert Talks About Resetting Priorities in Cardiology

 

AHA: Get With The Guidelines - Not Much Improvement

 

AIM-HIGH Trial - Take Home Message

 

    
www.deGomaMD.com
Copyright 2001-2011     Preventing Most Heart Attacks and Strokes since 2001     eMedical Consulting     All rights reserved